Cargando…
Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia
The risk factors for eosinophilic pneumonia (EP) remain unclear. We investigate the characteristics of patients with daptomycin (DAP)-induced EP and conducted a retrospective observational study. A total of 450 patients aged ≥ 18 years who received DAP (25 DAP with EP, 425 DAP without EP) were inclu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868239/ https://www.ncbi.nlm.nih.gov/pubmed/35203855 http://dx.doi.org/10.3390/antibiotics11020254 |
_version_ | 1784656219165687808 |
---|---|
author | Ishikawa, Kazuhiro Matsuo, Takahiro Tsuda, Yasumasa Rahman, Mahbubur Uehara, Yuki Mori, Nobuyoshi |
author_facet | Ishikawa, Kazuhiro Matsuo, Takahiro Tsuda, Yasumasa Rahman, Mahbubur Uehara, Yuki Mori, Nobuyoshi |
author_sort | Ishikawa, Kazuhiro |
collection | PubMed |
description | The risk factors for eosinophilic pneumonia (EP) remain unclear. We investigate the characteristics of patients with daptomycin (DAP)-induced EP and conducted a retrospective observational study. A total of 450 patients aged ≥ 18 years who received DAP (25 DAP with EP, 425 DAP without EP) were included. The median duration from the first DAP administration to EP onset was 18.0 days. Definite, probable, and possible DAP-induced EP were diagnosed in 0, 9, and 16 patients, respectively. The median age (DAP with EP, 72.0 years; DAP without EP, 64.0 years), DAP dosage/body weight (BW) (9.00 vs. 7.50 mg/kg), blood eosinophil count (cells/μL) (419 vs. 96), and the percentage of hemodialyzed patients (40.0% vs. 13.4%) were significantly higher in patients with EP than in patients without EP in the univariate analysis. In separate multivariate logistic regression analyses, age (odds ratio (OR), 1.03; 95% confidence interval (CI), 1.00–1.05), DAP dosage/BW (OR, 1.61; 95% CI, 1.25–2.07), and hemodialysis (OR, 4.42; 95% CI, 1.86–10.5) were significantly associated with DAP-induced EP. Clinicians may need to consider the potential factors associated with EP, especially in older patients, patients on hemodialysis, or patients who receive > 9.00 mg/kg of DAP. |
format | Online Article Text |
id | pubmed-8868239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88682392022-02-25 Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia Ishikawa, Kazuhiro Matsuo, Takahiro Tsuda, Yasumasa Rahman, Mahbubur Uehara, Yuki Mori, Nobuyoshi Antibiotics (Basel) Article The risk factors for eosinophilic pneumonia (EP) remain unclear. We investigate the characteristics of patients with daptomycin (DAP)-induced EP and conducted a retrospective observational study. A total of 450 patients aged ≥ 18 years who received DAP (25 DAP with EP, 425 DAP without EP) were included. The median duration from the first DAP administration to EP onset was 18.0 days. Definite, probable, and possible DAP-induced EP were diagnosed in 0, 9, and 16 patients, respectively. The median age (DAP with EP, 72.0 years; DAP without EP, 64.0 years), DAP dosage/body weight (BW) (9.00 vs. 7.50 mg/kg), blood eosinophil count (cells/μL) (419 vs. 96), and the percentage of hemodialyzed patients (40.0% vs. 13.4%) were significantly higher in patients with EP than in patients without EP in the univariate analysis. In separate multivariate logistic regression analyses, age (odds ratio (OR), 1.03; 95% confidence interval (CI), 1.00–1.05), DAP dosage/BW (OR, 1.61; 95% CI, 1.25–2.07), and hemodialysis (OR, 4.42; 95% CI, 1.86–10.5) were significantly associated with DAP-induced EP. Clinicians may need to consider the potential factors associated with EP, especially in older patients, patients on hemodialysis, or patients who receive > 9.00 mg/kg of DAP. MDPI 2022-02-16 /pmc/articles/PMC8868239/ /pubmed/35203855 http://dx.doi.org/10.3390/antibiotics11020254 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ishikawa, Kazuhiro Matsuo, Takahiro Tsuda, Yasumasa Rahman, Mahbubur Uehara, Yuki Mori, Nobuyoshi Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia |
title | Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia |
title_full | Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia |
title_fullStr | Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia |
title_full_unstemmed | Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia |
title_short | Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia |
title_sort | factors associated with daptomycin-induced eosinophilic pneumonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868239/ https://www.ncbi.nlm.nih.gov/pubmed/35203855 http://dx.doi.org/10.3390/antibiotics11020254 |
work_keys_str_mv | AT ishikawakazuhiro factorsassociatedwithdaptomycininducedeosinophilicpneumonia AT matsuotakahiro factorsassociatedwithdaptomycininducedeosinophilicpneumonia AT tsudayasumasa factorsassociatedwithdaptomycininducedeosinophilicpneumonia AT rahmanmahbubur factorsassociatedwithdaptomycininducedeosinophilicpneumonia AT ueharayuki factorsassociatedwithdaptomycininducedeosinophilicpneumonia AT morinobuyoshi factorsassociatedwithdaptomycininducedeosinophilicpneumonia |